PharmaCyte Biotech (PMCB) Net Cash Flow (2010 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Net Cash Flow of -$1.6 million for Q2 2026, down 28.92% year-over-year from -$2.2 million in Q2 2025, and down 132.84% quarter-over-quarter from $4.8 million in Q1 2026.
PharmaCyte Biotech (PMCB) Net Cash Flow (2010 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Net Cash Flow for 17 consecutive years, with -$1.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Cash Flow fell 28.92% year-over-year to -$1.6 million; the TTM figure through Apr 2026 stood at $3.4 million (up 109.79% YoY), while the FY2026 annual figure was $3.4 million, up 109.79% from the prior year.
- Net Cash Flow slipped to -$1.6 million in Q2 2026 per PMCB's latest filing, from $4.8 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $6.6 million in Q3 2023 and bottomed at -$17.5 million in Q3 2024.
- Historically, Net Cash Flow has averaged -$3.8 million across 5 years, with a median of -$2.6 million in 2022.
- On a YoY basis, Net Cash Flow climbed as much as 308.61% in 2023 and fell as far as 1346.47% in 2023.
- PharmaCyte Biotech's Net Cash Flow stood at -$5.3 million in 2022, then jumped by 76.53% to -$1.2 million in 2023, then slumped by 854.55% to -$11.8 million in 2024, then jumped by 118.89% to $2.2 million in 2025, then sank by 170.12% to -$1.6 million in 2026.
- Business Quant data shows PMCB's Net Cash Flow at -$1.6 million in Q2 2026, $4.8 million in Q1 2026, and $2.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | PharmaCyte Biotech | 4.30 Mn | 4.30 Mn | - | -1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -1.56 Mn |
| Apr 30, 2026 | -1.56 Mn |
| Jan 31, 2026 | 4.76 Mn |
| Jan 31, 2026 | 4.76 Mn |
| Oct 31, 2025 | 2.23 Mn |
| Oct 31, 2025 | 2.23 Mn |
| Jul 31, 2025 | -1.99 Mn |
| Jul 31, 2025 | -1.99 Mn |
| Apr 30, 2025 | -1.21 Mn |
| Apr 30, 2025 | -1.21 Mn |
| Jan 31, 2025 | -4.46 Mn |
| Jan 31, 2025 | -4.46 Mn |
| Oct 31, 2024 | -11.80 Mn |
| Oct 31, 2024 | -11.80 Mn |
| Jul 31, 2024 | -17.55 Mn |
| Jul 31, 2024 | -17.55 Mn |
| Apr 30, 2024 | -11.03 Mn |
| Apr 30, 2024 | -11.03 Mn |
| Jan 31, 2024 | -12.22 Mn |
| Jan 31, 2024 | -12.22 Mn |